Acute myeloid leukemia (AML) is no longer thought to be just a single disease; thus, each subtype needs to be treated differently. In this interview, Mark Levis, MD, PhD, from The Johns Hopkins Hospital, Baltimore, MD, talks to us about novel targeted agents for AML, including IDH inhibitors, FLT3 inhibitors and antimetabolites. Dr Levis highlights the pressure and rapid turnaround for molecular diagnostics to aid in this targeted treatment for each patient. This interview was recorded at the International Conference on Acute Myeloid Leukemia 2017, Estoril, Portugal by the European School of Hematology (ESH).
One size does not fit all: AML subtype treatment approaches
